Arrowhead Pharmaceuticals Presentation of Topline Data from Fazirsiran Phase 2 SEQUOIA Study
|DATE:||January 9, 2023|
|TIME:||8:30 AM EST|
About The Event
Join us for a virtual webcast with Arrowhead Pharmaceuticals to present topline data from the SEQUOIA Phase 2 study of fazirsiran and discuss the design for the planned Phase 3 study. Fazirsiran is a potential first-in-class investigational RNA interference (RNAi) therapy designed to reduce production of the mutant alpha-1 antitrypsin protein (Z-AAT) as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency. Fazirsiran is being developed under a collaboration and licensing agreement between Arrowhead and Takeda (TSE: 4502 / NYSE: TAK).